Introducing MyOmniSource... Dedicated to Making Growth Easy
Welcome to MyOmniSource, your online portal to a variety
of Omnitrope® (somatropin [rDNA origin] for injection)
services and support-including secure, virtually instant
access to the insurance approval status of your Omnitrope
Patient Approval Status
Simply log in to the secure, personalized portal that only you can access.
Omnitrope is a recombinant human growth hormone indicated for:
Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature.
Adult: Treatment of adults with either adult onset or childhood onset GHD.
Acute Critical Illness
Children with Prader-Willi Syndrome who are severely obese or have severe respiratory impairment—reports of sudden death
Active Proliferative or Severe Non-Proliferative Diabetic Retinopathy
Children with closed epiphyses
Known hypersensitivity to somatropin or excipients
Warnings and Precautions
Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk
Prader-Willi Syndrome in children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment. Discontinue treatment if these signs occur
Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin–in particular meningiomas in patients treated with radiation to the head for their first neoplasm
Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked. Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment
Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction
Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome, especially in adults): May occur frequently. Reduce dose as necessary
Hypopituitarism: Closely monitor other hormone replacement therapies
Hypothyroidism: May first become evident or worsen
Slipped Capital Femoral Epiphysis: May develop. Evaluate children with the onset of a limp or hip/knee pain
Progression of Preexisting Scoliosis: May develop
Otitis Media and Cardiovascular Disorders in Turner syndrome: Patients with Turner syndrome should be evaluated for otitis media and other ear disorders and monitored for cardiovascular disorders
Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain, especially children
Adverse events and death associated with benzyl alcohol: Formulations containing benzyl alcohol (5 mg/1.5 mL Omnitrope Cartridges and the Bacteriostatic Water for Injection diluent for the Omnitrope 5.8 mg/vial) should not be used in premature babies or neonates. Consider the combined daily metabolic load of benzyl alcohol from all sources
Other common somatropin-related adverse reactions include injection site reactions/rashes and lipoatrophy and headaches.
11β-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance doses
Pharmacologic Glucocorticoid Therapy and Supraphysiologic Glucocorticoid Treatment: Should be carefully adjusted
Cytochrome P450-Metabolized Drugs: Monitor carefully if used with somatropin
Oral Estrogen: Larger doses of somatropin may be required in women
Insulin and/or Oral Hypoglycemic Agents: May require adjustment
Use In Specific Populations
Pregnancy — Pregnancy Category B
Animal reproduction studies have not been conducted with Omnitrope. It is not known whether Omnitrope can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.
It is not known whether Omnitrope is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Omnitrope is administered to a nursing woman.
The safety and effectiveness of Omnitrope in patients aged 65 and over have not been evaluated in clinical studies. Elderly patients may be more sensitive to the action of somatropin, and therefore may be more prone to develop adverse reactions. A lower starting dose and smaller dose increments should be considered for older patients.
To report Suspected Adverse Reactions, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch